Melanotan II is a cyclic heptapeptide analog of alpha melanocyte stimulating hormone. It acts as a nonselective agonist across the melanocortin receptor family, with meaningful activity at MC1, MC3, MC4, and MC5 and minimal activity at the ACTH-specific MC2 receptor. Structural modifications, including norleucine in place of methionine, a D-phenylalanine substitution, aspartate-lysine cyclization, and terminal capping, give it resistance to enzymatic degradation and a longer half-life than native alpha-MSH. Reported half-life is roughly thirty to forty minutes intravenously and one to two hours subcutaneously, with subcutaneous bioavailability around eighty to ninety percent.

Unlike Melanotan I, Melanotan II crosses the blood brain barrier, which extends its signaling beyond peripheral pigmentation into central appetite, sexual, and autonomic circuits. It is not approved for human use in the US, Europe, Australia, or Ireland, and no phase three trials have been completed for any indication.

Mechanism across the melanocortin receptors

At the MC1 receptor on melanocytes, binding activates a Gs protein cascade that raises cyclic AMP, activates PKA, phosphorylates CREB, and upregulates the microphthalmia transcription factor, the master regulator of pigmentation. This drives tyrosinase activity and favors eumelanin, the brown-to-black antioxidant pigment associated with photoprotection. MC4 signaling in the arcuate nucleus is linked to reduced food intake, increased thermogenesis independent of intake, erectile response, and central oxytocin release, much of it characterized in animal models. MC3 activity relates to energy homeostasis and immune modulation.

Clinical signals and safety

Small human pigmentation studies dating to the 1990s reported measurable changes after only a handful of subcutaneous doses, with effect persisting about a week. Double-blind erectile dysfunction studies reported erections in most participants. Animal data describe metabolic effects, neuroprotection in nerve-injury and cisplatin-neuropathy models, and broad immune modulation, including reduced TNF-alpha, IL-6, and IL-8 alongside increased IL-10 and Treg activation. Tachyphylaxis develops within days of continuous dosing, so intermittent protocols are preferred.

Multiple case reports document melanomas and darkening nevi during use. The speaker notes there is no conclusive evidence the peptide causes melanoma and offers a mechanistic interpretation, while stressing that this remains hypothetical and that more randomized controlled data are needed. Unregulated online sourcing has prompted public warnings and has been tied to contamination and dosing risks.

Key clinical points

• Melanotan II is a nonselective melanocortin agonist at MC1, MC3, MC4, and MC5, with minimal MC2 activity; it crosses the blood brain barrier and carries central effects that Melanotan I does not.
• It is not FDA approved; available human evidence is limited to small trials, with most data preclinical or from case reports.
• Pigmentation is driven through MC1 and the MITF pathway favoring eumelanin; dosing is titrated to pigment response and skin type.
• Monitoring described includes full skin exams with nevi photography, blood pressure checks before and after injection, and baseline plus three-month CMP and CBC.
• Cautions include melanoma history, hypertension, PDE5 inhibitor combinations, priapism, pregnancy, and concurrent skin procedures or sun bed use.